My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Synthetic Biologics Inc (SYN)
SYN nyse mkt
United States
Synthetic Biologics

Synthetic Biologics Stock Analysis & Ratings

Synthetic Biologics Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The Synthetic Biologics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


SYN Stock Stats

Previous Close$0.42
Bid0.414 x 200
Ask0.42 x 3736
Today’s Range$0.42 - $0.42
52-Week Range$0.28 - $1.70
Average Volume1.62M
Market Cap$55.38M
P/E Ratio-1.0
Earnings DateNov 03, 2021

Company Description

Synthetic Biologics Inc

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Steven A. Shallcross
9605 Medical Center Drive, Rockville, MD, 20850, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was Synthetic Biologics’s price range in the past 12 months?
Synthetic Biologics lowest stock price was $0.28 and its highest was $1.70 in the past 12 months.
    What is Synthetic Biologics’s market cap?
    Synthetic Biologics’s market cap is $55.38M.
      What is Synthetic Biologics’s price target?
      The average price target for Synthetic Biologics is $2.50. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $2.50 ,the lowest forecast is $2.50. The average price target represents 496.09% Increase from the current price of $0.419.
        What do analysts say about Synthetic Biologics?
        Synthetic Biologics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Synthetic Biologics’s upcoming earnings report date?
          Synthetic Biologics’s upcoming earnings report date is Nov 03, 2021 which is in 6 days.
            How were Synthetic Biologics’s earnings last quarter?
            Synthetic Biologics released its earnings results on Aug 05, 2021. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
              Is Synthetic Biologics overvalued?
              According to Wall Street analysts Synthetic Biologics’s price is currently Undervalued.
                Does Synthetic Biologics pay dividends?
                Synthetic Biologics does not currently pay dividends.
                What is Synthetic Biologics’s EPS estimate?
                Synthetic Biologics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Synthetic Biologics have?
                Synthetic Biologics has 132,040,000 shares outstanding.
                  What happened to Synthetic Biologics’s price movement after its last earnings report?
                  Synthetic Biologics reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -1.961%.
                    Which hedge fund is a major shareholder of Synthetic Biologics?
                    Among the largest hedge funds holding Synthetic Biologics’s share is Fisher Asset Management LLC. It holds Synthetic Biologics’s shares valued at 76K.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis